Matthew Gline insider trades

Open-market stock purchases and sales by Matthew Gline, CEO at Roivant Sciences Ltd, from SEC Form 4 filings since Mar 7, 2022.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +140%.

Recent trades

DateStockTradeValue
Apr 16, 2026ROIV Roivant Sciences LtdSold$8.4M
Mar 31, 2026ROIV Roivant Sciences LtdSold (not open market)$8.4M
Mar 30, 2026ROIV Roivant Sciences LtdBought (not open market)—
Mar 30, 2026ROIV Roivant Sciences LtdSold (not open market)$1.4M
Mar 30, 2026ROIV Roivant Sciences LtdBought (not open market)$25M
Dec 15, 2025ROIV Roivant Sciences LtdSold$5M
Dec 15, 2025ROIV Roivant Sciences LtdSold (not open market)$81.1K
Dec 15, 2025ROIV Roivant Sciences LtdSold$12.3M
Dec 15, 2025ROIV Roivant Sciences LtdSold (not open market)$17.3M
Dec 15, 2025ROIV Roivant Sciences LtdSold$20.5M
Dec 15, 2025ROIV Roivant Sciences LtdSold (not open market)$28.8M
Dec 15, 2025ROIV Roivant Sciences LtdBought (not open market)—
Dec 15, 2025ROIV Roivant Sciences LtdBought (not open market)—
Dec 15, 2025ROIV Roivant Sciences LtdBought (not open market)—

Companies traded

  • ROIV Roivant Sciences Ltd: 1 buy, 16 sales, last Apr 16, 2026

Get free alerts when Matthew Gline files a new trade →